Daclatasvir Dihydrochloride and Insulin Glargine (U-300) Pens
Determining the interaction of Daclatasvir Dihydrochloride and Insulin Glargine (U-300) Pens and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: daclatasvir
Brand name: Daklinza
Synonyms: Daclatasvir
Generic Name: insulin glargine
Brand name: Basaglar KwikPen, Lantus, Lantus Solostar Pen, Toujeo SoloStar, Lantus OptiClik Cartridge, Toujeo Max SoloStar, Lantus SoloStar
Synonyms: Insulin glargine, Insulin Glargine
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Daclatasvir Dihydrochloride-Insulin glargine and lixisenatide
- Daclatasvir Dihydrochloride-Insulin glargine and lixisenatide Subcutaneous
- Daclatasvir Dihydrochloride-Insulin glargine, recombinant Subcutaneous
- Daclatasvir Dihydrochloride-Insulin glulisine
- Daclatasvir Dihydrochloride-Insulin Glulisine (Cartridges and Pens)
- Daclatasvir Dihydrochloride-Insulin Glulisine (Vials)
- Insulin Glargine (U-300) Pens-Daclizumab
- Insulin Glargine (U-300) Pens-Daclizumab Subcutaneous
- Insulin Glargine (U-300) Pens-Dacogen
- Insulin Glargine (U-300) Pens-Dacomitinib
- Insulin Glargine (U-300) Pens-Dactinomycin
- Insulin Glargine (U-300) Pens-Dactinomycin Injection